These studies reinfornce the importance of evaluation real-world treatment patterns when developing value-based reimbursement strategies. This latest set delves into renal cell carcinmoa.
Dr. Bruce Feinberg, Vice President and Chief Medical Officer at Cardinal Health Specialty Solutions stated, “With an increase focus on value-based care, which relies on real-world clinical evidence, clinical trial data no longer provides enough information to develop approrpirate reimbursement models.”
Cardinal Health has spent the last year publishing numerous studies on treatment patterns in leukemia and lymphoma care, focusing in on the economic impact of that care on patients.
To see the the abstracts from the ASCO meeting in full, click here.
